A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight

General Hospital Psychiatry

Volumn 36, Issue 1, 2014, Pages 13-18

  Huang, Hsiang ^a   Coleman, Shane ^b   Bridge, Jeffrey A ^c   Yonkers, Kimberly ^d   Katon, Wayne ^b  

^a CAMBRIDGE HEALTH ALLIANCE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d YALE UNIVERSITY   (United States)

Author keywords

Adverse birth outcomes; Antenatal; Antidepressants; Low birth weight; Pregnancy; Prenatal; Preterm birth

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; BIRTH WEIGHT; DRUG EFFECT; DRUG USE; EXPERIMENTAL DESIGN; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; META ANALYSIS; OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL CARE; PUBLICATION; PUERPERAL DEPRESSION; QUALITY CONTROL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SMALL FOR DATE INFANT; SYNDROME DELINEATION; SYSTEMATIC REVIEW;

ADVERSE BIRTH OUTCOMES; ANTENATAL; ANTIDEPRESSANTS; LOW BIRTH WEIGHT; PREGNANCY; PRENATAL; PRETERM BIRTH;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH; TREATMENT OUTCOME;

EID: 84891277403     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2013.08.002     Document Type: Article

References (54)

1. Gavin N.I., Gaynes B.N., Lohr K.N., Meltzer-Brody S., Gartlehner G., Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005, 106(5):1071-1083.
2. Grote N.K., Bridge J.A., Gavin A.R., Melville J.L., Iyengar S., Katon W.J. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010, 67(10):1012-1024.
3. Field T. Postpartum depression effects on early interactions, parenting, and safety practices: a review. Infant Behav Dev 2010, 33(1):1-6.
4. Yonkers K., Vigod S., Ross L. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol 2011, 117(4):961-977.
5. APA Practice guideline for the treatment of patients with major depressive disorder. American Psychiatric Association 2010, [cited 10/21/2012]; Available from:. http://psychiatryonline.org/content.aspxbookid=28§ionid=1667485, 3rd ed.
6. Andrade S.E., Gurwitz J.H., Davis R.L., Chan K.A., Finkelstein J.A., Fortman K., et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004, 191(2):398-407.
7. Cooper W.O., Willy M.E., Pont S.J., Ray W.A. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007, 196(6):e1-e5.
8. Martin J.A., Hamilton B.E., Ventura S.J., Osterman M.J., Kirmeyer S., Mathews T.J., et al. Births: final data for 2009. Natl Vital Stat Rep 2011, 60(1):1-70.
9. Udechuku A., Nguyen T., Hill R., Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 2010, 44(11):978-996.
10. Shah N.R., Bracken M.B. A systematic review and meta-analysis of prospective studies on the association between maternal cigarette smoking and preterm delivery. Am J Obstet Gynecol 2000, 182(2):465-472.
11. Yonkers K.A., Wisner K.L., Stewart D.E., Oberlander T.F., Dell D.L., Stotland N., et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009, 114(3):703-713.
12. Ross Le, Grigoriadis S., Mamisashvili L., Vonderporten E.H., Roerecke M., Rehm J., et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 2013, 70(4):436-443.
13. Lipsey M., Wilson D. Practical meta-analysis 2001, Sage Publications, Thousand Oaks, CA.
14. Grzeskowiak L.E., Gilbert A.L., Morrison J.L. Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors. J Clin Psychopharmacol 2012, 32(5):615-621.
15. El Marroun H., Jaddoe V.W., Hudziak J.J., Roza S.J., Steegers E.A., Hofman A., et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 2012, 69(7):706-714.
16. Klieger-Grossmann C., Weitzner B., Panchaud A., Pistelli A., Einarson T., Koren G., et al. Pregnancy outcomes following use of escitalopram. J Clin Pharmacol 2012, 52(5):766-770.
17. Nordeng H., van Gelder M.M., Spigset O., Koren G., Einarson A., Eberhard-Gran M. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012, 32(2):186-194.
18. Yonkers K.A., Norwitz E.R., Smith M.V., Lockwood C.J., Gotman N., Luchansky E., et al. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology 2012, 23(5):677-685.
19. Colvin L., Slack-Smith L., Stanley F.J., Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011, 91(3):142-152.
20. Latendresse G., Ruiz R.J. Maternal corticotropin-releasing hormone and the use of selective serotonin reuptake inhibitors independently predict the occurrence of preterm birth. J Midwifery Womens Health 2011, 56(2):118-126.
21. Roca A., Garcia-Esteve L., Imaz M.L., Torres A., Hernandez S., Botet F., et al. Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose. J Affect Disord 2011, 135(1-3):208-215.
22. Einarson A., Choi J., Einarson T.R., Koren G. Adverse effects of antidepressant use in pregnancy: an evaluation of fetal growth and preterm birth. Depress Anxiety 2010, 27(1):35-38.
23. Lewis A.J., Galbally M., Opie G., Buist A. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust N Z J Psychiatry 2010, 44(5):482-487.
24. Reis M., Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010, 40(10):1723-1733.
25. Lund N., Pedersen L.H., Henriksen T.B. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009, 163(10):949-954.
26. Toh S., Mitchell A.A., Louik C., Werler M.M., Chambers C.D., Hernandez-Diaz S. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 2009, 29(6):555-560.
27. Wisner K.L., Sit D.K., Hanusa B.H., Moses-Kolko E.L., Bogen D.L., Hunker D.F., et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009, 166(5):557-566.
28. Maschi S., Clavenna A., Campi R., Schiavetti B., Bernat M., Bonati M. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 2008, 115(2):283-289.
29. Davis R.L., Rubanowice D., McPhillips H., Raebel M.A., Andrade S.E., Smith D., et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007, 16(10):1086-1094.
30. Lennestal R., Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007, 27(6):607-613.
31. Pearson K.H., Nonacs R.M., Viguera A.C., Heller V.L., Petrillo L.F., Brandes M., et al. Birth outcomes following prenatal exposure to antidepressants. J Clin Psychiatry 2007, 68(8):1284-1289.
32. Suri R., Altshuler L., Hellemann G., Burt V.K., Aquino A., Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007, 164(8):1206-1213.
33. Djulus J., Koren G., Einarson T.R., Wilton L., Shakir S., Diav-Citrin O., et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006, 67(8):1280-1284.
34. Wen S.W., Yang Q., Garner P., Fraser W., Olatunbosun O., Nimrod C., et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006, 194(4):961-966.
35. Sivojelezova A., Shuhaiber S., Sarkissian L., Einarson A., Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 2005 Dec, 193(6):2004-2009.
36. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. JAMA Pediatrics 2004 Apr, 158(4):312-316.
37. Casper R.C., Fleisher B.E., Lee-Ancajas J.C., Gilles A., Gaylor E., DeBattista A., et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003, 142(4):402-408.
38. Simon G.E., Cunningham M.L., Davis R.L. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002, 159(12):2055-2061.
39. Ericson A., Kallen B., Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999, 55(7):503-508.
40. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335(14):1010-1015.
41. Pastuszak A., Schick-Boschetto B., Zuber C., Feldkamp M., Pinelli M., Sihn S., et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993, 269(17):2246-2248.
42. Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998, 52(6):377-384.
43. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
44. Greenhouse J., Iyengar S. Sensitivity analyses and diagnostics. HM C, LV H, editors 1994, New York, New York, Russell Sage Foundation.
45. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
46. Duval S., Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56(2):455-463.
47. Sutton A.J., Duval S.J., Tweedie R.L., Abrams K.R., Jones D.R. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000, 320(7249):1574-1577.
48. Peters J.L., Sutton A.J., Jones D.R., Abrams K.R., Rushton L. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med 2007, 26(25):4544-4562.
49. Lattimore K.A., Donn S.M., Kaciroti N., Kemper A.R., Neal C.R., Vazquez D.M. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 2005, 25(9):595-604.
50. Oberlander T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008, 192(5):338-343.
51. Cohen L.S., Altshuler L.L., Harlow B.L., Nonacs R., Newport D.J., Viguera A.C., et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006, 295(5):499-507.
52. Luoma I., Tamminen T., Kaukonen P., Laippala P., Puura K., Salmelin R., et al. Longitudinal study of maternal depressive symptoms and child well-being. J Am Acad Child Adolesc Psychiatry 2001, 40(12):1367-1374.
53. Kelly R.H., Russo J., Katon W. Somatic complaints among pregnant women cared for in obstetrics: normal pregnancy or depressive and anxiety symptom amplification revisited. Gen Hosp Psychiatry 2001, 23(3):107-113.
54. Katon W.J., Russo J.E., Melville J.L., Katon J.G., Gavin A.R. Depression in pregnancy is associated with preexisting but not pregnancy-induced hypertension. Gen Hosp Psychiatry 2012, 34(1):9-16.